Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy

Autor:	Shuangshuang Liu, Shuguo Wang, Zhiluo Yang, Wei Yu, Shupei Ma, Xia Zhou
Rok vydání:	2019
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty Newly diagnosed Immunophenotyping 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Lymphocyte Count Molecular Targeted Therapy Cyclophosphamide neoplasms Aged Neoplasm Staging Aged 80 and over business.industry Hematology Middle Aged Lymphocyte Subsets Treatment Outcome Doxorubicin Vincristine Case-Control Studies 030220 oncology & carcinogenesis Peripheral blood lymphocyte Retreatment Prednisone Female Rituximab Lymphoma Large B-Cell Diffuse business Biomarkers 030215 immunology Lymphocyte subsets medicine.drug
Zdroj:	Leukemia & Lymphoma. 60:2909-2916
ISSN:	1029-2403 1042-8194
DOI:	10.1080/10428194.2019.1617861
Popis:	The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a727d3b297588b9ad0aa810d1dc5e13a https://doi.org/10.1080/10428194.2019.1617861 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.